Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Percheron Therapeutics's Enterprise Value is $1.15 Mil.
Percheron Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.21 Mil. Therefore, Percheron Therapeutics's EV-to-EBIT ratio for today is -0.19.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Percheron Therapeutics (OTCPK:PERCF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Percheron Therapeutics's current Enterprise Value is $1.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Percheron Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.21 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Percheron Therapeutics's EV-to-EBITDA for today is:
Percheron Therapeutics's current Enterprise Value is $1.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Percheron Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.18 Mil.
Percheron Therapeutics's current Enterprise Value is $1.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Percheron Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.
Percheron Therapeutics's current Enterprise Value is $1.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Percheron Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.40 Mil.
Percheron Therapeutics's current Enterprise Value is $1.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Percheron Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Percheron Therapeutics Enterprise Value Related Terms
Percheron Therapeutics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Percheron Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Percheron Therapeutics Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Percheron Therapeutics's Enterprise Value falls into.
Percheron Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Percheron Therapeutics's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Percheron Therapeutics (PERCF) has a Enterprise Value of $1.15 Mil as of Jun. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Percheron Therapeutics and its competitors.
Is Percheron Therapeutics' Enterprise Value too high?
Percheron Therapeutics' current Enterprise Value is $1.15 Mil.
How does Percheron Therapeutics' Enterprise Value compare to ZTS?
Percheron Therapeutics' Enterprise Value of $1.15 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Percheron Therapeutics and its competitors. Percheron Therapeutics's current Enterprise Value is $1.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current Enterprise Value of $1.15 Mil. The current Enterprise Value is $1.15 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current Enterprise Value is $1.15 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PERCF has been successfully added to your 